tbuckley/cabot-search huggingface dataset:
Health Care Worker SARS-CoV-2 Infection Is Flying Under the Radar
Authors: Bridget M. Kuehn
Journal: JAMA (2020)

A high percentage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among health care workers appear to go undetected, often because they have mild or no symptoms and workplace testing isn't sufficient, investigators from a multistate hospital network reported.
Zoonotic infection with swine A/H1avN1 influenza virus in a child, Germany, June 2020
Authors: Ralf Dürrwald, Marianne Wedde, Barbara Biere, Djin-Ye Oh, Martina Heßler-Klee, Christian Geidel, Renate Volmer, Anja Maria Hauri, Kai Gerst, Andrea Thürmer, Sandra Appelt, Janine Reiche, Susanne Duwe, Silke Buda, Thorsten Wolff, Walter Haas
Journal: Eurosurveillance (2020)

A zoonotic A/sw/H1 av N1 1C.2.2 influenza virus infection was detected in a German child that presented with influenza-like illness, including high fever. There was a history of close contact with pigs 3 days before symptom onset. The child recovered within 3 days. No other transmissions were observed. Serological investigations of the virus isolate revealed cross-reactions with ferret antisera against influenza A(H1N1)pdm09 virus, indicating a closer antigenic relationship with A(H1N1)pdm09 than with the former seasonal H1N1 viruses.
TCT CONNECT-56 Prolonged Dual Antiplatelet Therapy in Patients With or Without Prior Myocardial Infarction: An Updated Systematic Review and Meta-Analysis
Authors: Mauro Chiarito, Davide Cao, Matteo Pagnesi, Johny Nicolas, Matteo Nardin, Samantha Sartori, Bimmer Claessen, Rishi Chandiramani, Giulio Stefanini, George Dangas, Roxana Mehran
Journal: Journal of the American College of Cardiology (2020)
Additional Concerns Regarding Children With Coronavirus Disease 2019
Authors: Yi-Ching Chen, Cheng-Hsun Chiu
Journal: JAMA Pediatrics (2020)

Riccardo Castagnoli, MD; Martina Votto, MD; Amelia Licari, MD; Ilaria Brambilla, MD, PhD; Raffaele Bruno, MD; Stefano Perlini, MD; Francesca Rovida, PhD; Fausto Baldanti, MD; Gian Luigi Marseglia, MD
New Therapeutics for Hepatitis B: The Road to Cure
Authors: Susanna Naggie, Anna S. Lok
Journal: Annual Review of Medicine (2020)

Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable treatment response, necessitating indefinite treatment in the majority of cases, have resulted in low uptake of testing and treatment, particularly in regions where comprehensive primary care is lacking and access to affordable testing and treatment is limited. Multiple targeted therapies are now in early human study with the primary goal to achieve persistent HBV DNA and hepatitis B surface antigen suppression after a finite course of treatment, which is referred to as functional cure. This article summarizes the current therapies for HBV infection and discusses the limitations of these therapies, novel approaches to HBV cure, and therapeutic endpoints of clinical trials aimed to cure hepatitis B.
Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand
Authors: Clementine Labrosciano, Dennis Horton, Tracy Air, Rosanna Tavella, John F. Beltrame, Christopher J. Zeitz, Harlan M. Krumholz, Robert J.T. Adams, Ian A. Scott, Martin Gallagher, Sadia Hossain, Saranya Hariharaputhiran, Isuru Ranasinghe
Journal: European Journal of Heart Failure (2020)
TCT CONNECT-10 Anatomy of Human Accessory Renal Artery Peri-Arterial Renal Sympathetic Nerve for Renal Denervation
Authors: Yu Sato, Rika Kawakami, Hiroyuki Jinnouchi, Atsushi Sakamoto, Anne Cornelissen, Masayuki Mori, Kenji Kawai, Leslie Coleman, Shannon Nash, Neil Barman, Maria Romero, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-52 Angiographic Complications in Primary Angioplasty: Influence of Age (Analysis From 2,121 Consecutive Patients)
Authors: Felipe Falcao, Fabiano Cantarelli, Rodrigo Cantarelli, Manuela Moreira, Flavio Mota, Antônio Raimundo, Henrique Mota, Martynelly Santos, Daniel Cruz, Marcelo Parente, Flavio Oliveira
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-76 Do People Living With HIV Have Different Outcomes Following Transcatheter Aortic Valve Replacement? Insights From the National Inpatient Sample
Authors: Bertrand Ebner, Jelani Grant, Louis Vincent, Jennifer Manning, Neal Olarte, Odunayo Olorunfemi, Rosario Colombo, Claudia Martinez
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-127 Comparison of Procedural Outcomes in Transcatheter Aortic Valve Replacement With Mechanically Expanded Valve Versus Self-Expandable Valve: A Systematic Review and Meta-Analysis
Authors: Hamza Hafeez, Khawaja Akhtar, Yusra Nasir, Khawaja Junaid Akhtar, Ali Jafry, Vijay Pratap Singh, Abdul Haseeb, Muhammad Farooqi, Talla Rousan
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-179 In Vivo Safety of the 10-F Reitan Catheter Temporary Percutaneous Mechanical Circulatory Support (pMCS) Device
Authors: Grigoris Karamasis, L. Christian Napp, Guenes Dogan, Arjang Ruhparwar, Bastian Schmack, Oyvind Reitan, Ida Zundorf, Tobias Giering, Tobias Walker, Thomas Keeble
Journal: Journal of the American College of Cardiology (2020)
What to expect for the influenza season 2020/21 with the ongoing COVID-19 pandemic in the World Health Organization European Region
Authors: Cornelia Adlhoch, Richard Pebody
Journal: Eurosurveillance (2020)

Preview this article: What to expect for the influenza season 2020/21 with the ongoing COVID-19 pandemic in the World Health Organization European Region, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/25/42/eurosurv-25-42-1-1.gif
Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis
Authors: Lingdi Yin, Ning Pu, Elizabeth Thompson, Yi Miao, Christopher Wolfgang, Jun Yu
Journal: Clinical Cancer Research (2020)

To evaluate somatic mutations, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in patients with Pancreatic ductal adenocarcinoma (PDAC) with pathologic complete response (pCR) to neoadjuvant therapy (NAT) and find their associations with outcome.Thirty-six patients with PDAC with pCR were identified from 2009 to 2017. Macrodissection was performed on resected specimens to isolate DNA from 332 regions of interest including fibrosis, normal duct, normal parenchyma, and undefined ductal cells (UDCs). Cell-free DNA and CTCs were also extracted. Next-generation sequencing was used to detect mutations of KRAS, CDKN2A, SMAD4, TP53, GNAS, and BRAF.KRAS mutation was detected in UDCs and fibrosis while SMAD4, TP53, and GNAS were only seen in UDCs. Patients with TP53 mutation showed relatively worse overall survival (HR, 3.596, 95% CI, 0.855-15.130; P = 0.081). Five patients available for CTCs data were all positive for CTCs and seven of 16 patients with pCR were detected with ctDNA at surgery. We proposed a new concept of regression assessment combining genomic analysis of resected specimens and liquid biopsy data for PDAC, namely, molecular complete response (mCR). Three of six patients with mCR recurred as compared with six in 15 non-mCR patients. Seven of 15 non-mCR patients died during follow-up, while there was only one in six patients with mCR.This study first reports that somatic mutations, CTCs, and ctDNA existed even in patients with PDAC with pCR to NAT, which could possibly predict early recurrence and reduced survival. The current regression evaluation system of PDAC needs to be reassessed at a molecular level.
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the United Kingdom – a cross-sectional, observational survey.
Authors: M Maiden, J Maclennan, Rodrigues Cmc., H B Bratcher, A Lekshmi, A Finn, J Oliver, M Wootton, S Ray, C Cameron, A Smith, P T Heath, A Bartolf, T Nolan, S Hughes, A Varghese, Snape, R Sewell, R Cunningham, A Stolton, C Kay, K Palmer, D Baxter, D Suggit, C S Zipitis, N Pemberton, K A Jolley, J E Bray, O B Harrison, S N Ladhani, A J Pollard, R Borrow, S J Gray, C Trotter
Journal: The Lancet Infectious Diseases (2020)
TCT CONNECT-49 Who Needs a Cardiologist for AMI Diagnosis? Progress of Transforming a Behemoth Telemedicine Program With Artificial Intelligence
Authors: Sameer Mehta, Francisco Fernandez, Carlos Villagran, Daniel Vieira, Gladys Pinto, Samantha Quintero, Yogaraja Vijayan, Daniel Pinos, Nino Coutelle, Carmen Sanchez, Lilly Prieto, Saleha Ozair
Journal: Journal of the American College of Cardiology (2020)
Production of Megakaryocytes and Platelets from Common Marmoset (Callithrix jacchus) ES Cells by Constitutive Expression of tal1/scl Gene.
Authors: Ryo Kurita, Tomoko Yokoo, Erika Sasaki, Yan Dong, Youko Suehiro, Yoshikuni Tanioka, Yasushi Soda, Norio Komatsu, Kenzaburo Tani
Journal: Blood (2006)
TCT CONNECT-466 New Pacemaker Implantation Following Transcatheter Aortic Valve Replacement
Authors: Maurizio Taramasso, Shirai Shinichi, Masaomi Hayashi, Tomohiro Kawaguchi, Yoshio Arai, Kenji Ando, Toru Naganuma, Kazuki Mizutani, Motoharu Araki, Norio Tada, Futoshi Yamanaka, Minoru Tabata, Hiroshi Ueno, Kensuke Takagi, Yusuke Watanabe, Masanori Yamamoto, Kentaro Hayashida, Mizuki Miura
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-361 Impact of Pulmonary Hypertension on MitraClip Short-Term Outcomes: Nationwide Representative Study
Authors: Omar Abdelfattah, Anas Saad, Mohamed Gad, Medhat Farwati, Toshiaki Isogai, Keerat Rai Ahuja, Essa Hariri, Shashank Shekhar, Rhonda Miyasaka, Serge Harb, Amar Krishnaswamy, Samir Kapadia
Journal: Journal of the American College of Cardiology (2020)
Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season
Authors: Carolina M. Andrade, Hannah Fleckenstein, Richard Thomson-Luque, Safiatou Doumbo, Nathalia F. Lima, Carrie Anderson, Julia Hibbert, Christine S. Hopp, Tuan M. Tran, Shanping Li, Moussa Niangaly, Hamidou Cisse, Didier Doumtabe, Jeff Skinner, Dan Sturdevant, Stacy Ricklefs, Kimmo Virtaneva, Muhammad Asghar, Manijeh Vafa Homann, Louise Turner, Joana Martins, Erik L. Allman, Marie-Esther N’Dri, Volker Winkler, Manuel Llinás, Catherine Lavazec, Craig Martens, Anna Färnert, Kassoum Kayentao, Aissata Ongoiba, Thomas Lavstsen, Nuno S. Osório, Thomas D. Otto, Mario Recker, Boubacar Traore, Peter D. Crompton, Silvia Portugal
Journal: Nature Medicine (2020)
TCT CONNECT-336 Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis
Authors: Richard Jung, Trevor Simard, Creigthon Don, Pietro Di Santo, Marianna Adamo, Francesca Valentini, Tomás Benito-González, Felipe Fernandez-Vazquez, Rodrigo Estevez-Loureiro, Nicolina Conti, Claudio Rapezzi, Elena Biagini, Simon Parlow, Risa Shorr, Amos Levi, Jose Francisco Diaz Fernandez, Dan Haberman, Sala Alessandra, Mohamad Alkhouli, Claudia Marini, Marta Bargagna, Davide Schiavi, Paolo Denti, Nicola Buzzatti, Mark Hynes, Thierry Mesana, Marino Labinaz, Sinisa Markovic, Federico Pappalardo, Maurizio Taramasso, Benjamin Hibbert
Journal: Journal of the American College of Cardiology (2020)
Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate?
Authors: Jianxiong Jiang, Ying Yu
Journal: Medicinal Research Reviews (2020)

Abstract Acute brain ischemia accounts for most of stroke cases and constitutes a leading cause of deaths among adults and permanent disabilities in survivors. Currently, the intravenous thrombolysis is the only available medication for ischemic stroke; mechanical thrombectomy is an emerging alternative treatment for occlusion of large arteries and has shown some promise in selected subsets of patients. However, the overall narrow treatment window and potential risks largely limit the patient eligibility. New druggable targets are needed to innovate the treatment of brain ischemia. As the rate‐limiting enzyme in the biosyntheses of prostanoids, cyclooxygenase (COX), particularly the inducible isoform COX‐2, has long been implicated in mechanisms of acute stroke‐induced brain injury and inflammation. However, the notion of therapeutically targeting COX has been diminished over the past two decades due to significant complications of the cardiovascular and cerebrovascular systems caused by long‐term use of COX‐2 inhibitor drugs. New treatment strategies targeting the downstream prostanoid signaling receptors regulating the deleterious effects of COX cascade have been proposed. As such, a large number of selective small molecules that negatively or positively modulate these important inflammatory regulators have been evaluated for neuroprotection and other beneficial effects in various animal models of brain ischemia. These timely preclinical studies, though not yet led to clinical innovation, provided new insights into the regulation of inflammatory reactions in the ischemic brain and could guide drug discovery efforts aiming for novel adjunctive strategies, along with current reperfusion therapy, to treat acute brain ischemia with higher specificity and longer therapeutic window.
TCT CONNECT-14 Outcomes of Myocardial Infarction With Nonobstructive Coronary Artery Disease Among Veterans: An Analysis From the Department of Veterans Affairs Clinical Assessment Reporting and Tracking Program
Authors: Christopher Kovach, Annika Hebbe, Colin O'Donnell, Mary Plomondon, Aref Rahman, Suresh Mulukutla, Stephen Waldo, Javier Valle
Journal: Journal of the American College of Cardiology (2020)
Absence of <i>Helicobacter</i> spp in the liver of patients with primary or metastatic liver cancer
Authors: Nicola Coppola, Giorgio de Stefano, Cecilia Marrocco, Ferdinando Scarano, Carlo Scolastico, Luciano Tarantino, Felice Piccinino, Evangelista Sagnelli, Antonio Giorgio, Pietro Filippini
Journal: Hepatology (2002)
TCT CONNECT-1 Early Feasibility Study of the Cardioband Tricuspid System for Functional Tricuspid Regurgitation: 30-Day Outcomes
Authors: William Gray, Scott Lim, Robert Smith, Susheel Kodali, Robert Kipperman, Mackram Eleid, Mark Reisman, Brian Whisenant, Jyothy Puthumana, Sandra Abramson, Dale Fowler, Paul Grayburn, Rebecca Hahn, Konstantinos Koulogiannis, Sorin Pislaru, Todd Zwink, Michael Minder, Abdellaziz Dahou, Charles Davidson
Journal: Journal of the American College of Cardiology (2020)
Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors
Authors: Mihai I. Truica, Michael C. Burns, Huiying Han, Sarki A. Abdulkadir
Journal: Cancer Research (2020)

MYC is a highly validated oncogenic transcription factor and cancer target. However, the disordered nature of this protein has made it a challenging target, with no clinical stage, direct small-molecule MYC inhibitors available. Recent work leveraging a large in silico chemical library and a rapid in vivo screen has expanded the chemotypes of direct small-molecule inhibitors (MYCi). Novel MYCi represent a class of improved MYC chemical probes that bind directly to MYC to inhibit its function and to promote its degradation by enhancing GSK3β-mediated phosphorylation. One of these compounds, MYCi975, has shown remarkable tolerability and efficacy in vivo and is associated with a selective effect on MYC target gene expression. Additional effects of MYCi on the tumor immune microenvironment including immune cell infiltration and upregulation of PD-L1 expression provide a rationale for combining MYCi with anti-PD-1/PD-L1 therapy to enhance antitumor efficacy. Our strategy for developing MYCi demonstrates an efficient way to identify selective and well-tolerated MYC inhibitors. The new MYCi provide tools for probing MYC function and serve as starting points for the development of novel anti-MYC therapeutics.
TCT CONNECT-118 Transaortic Flow in Aortic Stenosis: Stroke Volume Index Versus Systolic Flow Rate
Authors: Priya Bansal, Aneel Maini, Divyesh Doddapaneni, Sanjay Chandrasekhar, John Merriam, Andrew Fahmy, Arye Lavin, Sierra Conine, Hamza Lodhi, Adithya Mathews, Houman Khalili, Brij Maini
Journal: Journal of the American College of Cardiology (2020)
Risk for In-Hospital Complications Associated with COVID-19 and Influenza — Veterans Health Administration, United States, October 1, 2018–May 31, 2020
Authors: Jordan Cates, Cynthia Lucero-Obusan, Rebecca M. Dahl, Patricia Schirmer, Shikha Garg, Gina Oda, Aron J. Hall, Gayle Langley, Fiona P. Havers, Mark Holodniy, Cristina V. Cardemil
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Coronavirus disease 2019 (COVID-19) is primarily a respiratory illness, although increasing evidence indicates that infection with SARS-CoV-2, the virus that causes COVID-19, can affect multiple organ systems (1).Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking.To assess complications of COVID-19 and influenza, electronic health records (EHRs) from 3,948 hospitalized patients with COVID-19 (March 1-May 31, 2020) and 5,453 hospitalized patients with influenza (October 1, 2018-February 1, 2020) from the national Veterans Health Administration (VHA), the largest integrated health care system in the United States,* were analyzed.Using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes, complications in patients with laboratory-confirmed COVID-19 were compared with those in patients with influenza.Risk ratios were calculated and adjusted for age, sex, race/ethnicity, and underlying medical conditions; proportions of complications were stratified among patients with COVID-19 by race/ethnicity.Patients with COVID-19 had almost 19 times the risk for acute respiratory distress syndrome (ARDS) than did patients with influenza, (adjusted risk ratio [aRR] = 18.60; 95% confidence interval [CI] = 12.40-28.00),and more than twice the risk for myocarditis (2.56; 1.17-5.59),deep vein thrombosis (2.81; 2.04-3.87),pulmonary embolism (2.10; 1.53-2.89),intracranial hemorrhage (2.85; 1.35-6.03),acute hepatitis/liver failure (3.13; 1.92-5.10),bacteremia (2.46; 1.91-3.18),and pressure ulcers (2.65; 2.14-3.27).The risks for exacerbations of asthma (0.27; 0.16-0.44)and chronic obstructive pulmonary disease (COPD) (0.37; 0.32-0.42)were lower among patients with COVID-19 than among those with influenza.The percentage of COVID-19 patients who died while hospitalized (21.0%) was more than five times that of influenza patients (3.8%), and the duration of hospitalization was almost three times longer for COVID-19 patients.Among patients with COVID-19, the risk for respiratory, neurologic, and renal complications, and sepsis was higher among non-Hispanic Black or African American (Black) patients, patients of other * https://www.va.gov/vetdata/docs/pocketcards/fy20q2.pdf.
HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C
Authors: Chun Tao Wai, Chi-Jen Chu, Munira Hussain, Anna S. F. Lok
Journal: Hepatology (2002)

Hepatitis B virus (HBV) genotype and precore/core promoter mutations have been implicated in spontaneous and interferon alfa (IFN-α)—related hepatitis B e antigen (HBeAg) seroconversion. We performed a retrospective analysis of a previously reported randomized controlled trial to determine the effects of HBV genotype and precore/core promoter mutations on IFN-α response in patients with HBeAg-positive chronic hepatitis. Clinical data and stored sera from 109 (95%) patients in the original trial were analyzed. Seventy-three patients received IFN-α and 34 received no treatment (controls). Almost all patients had HBV genotypes B (38%) and C (60%). Antiviral response was achieved in 39% and 17% of IFN-α—treated patients ( P = 0.03) and in 10% and 8% of untreated controls ( P = 0.88) with HBV genotype B and C, respectively. Multivariate analysis identified HBV genotype B, elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV-DNA levels but not IFN-α treatment as independent factors associated with antiviral response. Among the 66 patients with elevated pretreatment ALT level, antiviral response was achieved in 57% and 21% of IFN-α—treated patients ( P = 0.019), and in 25% and 8% of untreated controls ( P = 0.45) with HBV genotype B and C, respectively. Multivariate analysis showed that genotype B and low pretreatment HBV-DNA levels were independent predictors of antiviral response. In conclusion, our data showed that HBV genotype B was associated with a higher rate of IFN-induced HBeAg clearance compared with genotype C. Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B. (Hepatology2002;36:1425-1430).
TCT CONNECT-369 Real-World Safety and Efficacy Outcomes of the Pioneer Plus Catheter in Endovascular Revascularization of Lower Extremity Chronic Total Occlusions
Authors: Azfar Sheikh, Fiorella Llanos-Chea, Qurat-ul-ain Jelani, Mahesh Anantha Narayanan, Robert Attaran, Marabel Schneider, Costin Ionescu, Christopher Regan, Sameer Nagpal, Kim Smolderen, Carlos Mena-Hurtado
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-487 MIDAS Has Only Trivial Impact on PPM Implantation Using the Largest Self-Expandable TAVR-Device
Authors: Verena Veulemans, Derk Frank, Hatim Seoudy, Steffen Wundram, Shazia Afzal, Kerstin Piayda, Oliver Maier, Amin Polzin, Christian Jung, Ralf Westenfeld, Norbert Frey, Tobias Zeus
Journal: Journal of the American College of Cardiology (2020)
Distinct integrin activation pathways for effector and regulatory T cell trafficking and function
Authors: Hao Sun, Frederic Lagarrigue, Hsin Wang, Zhichao Fan, Miguel Alejandro Lopez-Ramirez, John T. Chang, Mark H. Ginsberg
Journal: The Journal of Experimental Medicine (2020)

Integrin activation mediates lymphocyte trafficking and immune functions. Conventional T cell (Tconv cell) integrin activation requires Rap1-interacting adaptor molecule (RIAM). Here, we report that Apbb1ip-/- (RIAM-null) mice are protected from spontaneous colitis due to IL-10 deficiency, a model of inflammatory bowel disease (IBD). Protection is ascribable to reduced accumulation and homing of Tconv cells in gut-associated lymphoid tissue (GALT). Surprisingly, there are abundant RIAM-null regulatory T cells (T reg cells) in the GALT. RIAM-null T reg cells exhibit normal homing to GALT and lymph nodes due to preserved activation of integrins αLβ2, α4β1, and α4β7. Similar to Tconv cells, T reg cell integrin activation and immune function require Rap1; however, lamellipodin (Raph1), a RIAM paralogue, compensates for RIAM deficiency. Thus, in contrast to Tconv cells, RIAM is dispensable for T reg cell integrin activation and suppressive function. In consequence, inhibition of RIAM can inhibit spontaneous Tconv cell-mediated autoimmune colitis while preserving T reg cell trafficking and function.
TCT CONNECT-239 Complications and Failure Modes of Coronary Microcatheters. Insights From the Manufacturer and User Facility Device Experience (MAUDE) Database
Authors: Michael Megaly, Ramy Sedhom, Ashish Pershad, Evangelia Vemmou, Ilias Nikolakopoulos, Judit Karacsonyi, Marwan Saad, Amgad Mentias, Santiago Garcia, Dimitrios Karmpaliotis, Mohaned Egred, M. Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2020)